Positive topline results from the phase 3 GLOW2 trial suggest that tarcocimab tedromer (Zenkuda), an investigational anti–vascular endothelial growth factor (VEGF) biologic, may offer durable disease ...
A new system that uses artificial intelligence (AI) to assess cardiovascular risk based on images of the eye captured during ...
A new system that uses artificial intelligence (AI) to assess cardiovascular risk based on images of the eye captured during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results